Boards of Directors

Global Board of Directors

David Bell, Grifols USA - Chair
Bernhard Ehmer, Biotest AG
Karen Etchberger, CSL Behring
Kevin Lane, Bio Products Laboratory
Paolo Marcucci, Kedrion SpA
Matthew Walker, Shire

Europe Board of Directors

Oliver Schmitt, CSL Behring GmbH - Chair
Silvio Audisio, Kedrion
Paul Boeckmann, Bio Products Laboratory
Thierry Heinrich, Grifols Deutschland GmbH
Eric Thomas, Biotest
Kasha Witkos, Shire

North America Board of Directors

Paul Blanchfield, Shire - Chair
Neal Fitzpatrick, Kedrion Biopharma, Inc.
Bob Lojewski, CSL Behring
Ken McNish, Bio Products Laboratory
Laura Saward, Emergent BioSolutions Inc.
Bill Zabel, Grifols USA

Source Board of Directors

Peter Allen, Grifols Plasma Operations
Jay Bae, GCAM, Inc.
Bill Bees, Prometic Plasma Resources
Roger Brinser, BioLife Plasma Services/Shire - Chair
Ileana Carlisle, Biotest Pharmaceuticals Inc.
Michael Deem, CSL Plasma
Rob Jardeleza, BPL Plasma
Milan Maly, UNICAplasma s.r.o.
Rudolf Meixner, Europlasma GmbH
Paolo Melloni, Kedrion Biopharma
David Morad, Southern Blood Services
Larry Moss, The Interstate Companies

PPTA News

PPTA Highlights Importance of Patient Access to Plasma Protein Therapies +

On July 16, the Plasma Protein Therapeutics Association (PPTA) submitted comments following the Trump administration’s “American Patients First” drug policy blueprint. In any discussions impacting the ability of individuals living with rare, chronic, and life-threatening diseases, PPTA remains steadfast to its mission to promote the availability of and access to safe and effective plasma protein therapies for all patients in the world.
Read More
Statement on Romanian Competition Council +

To our big surprise representatives from the Romanian Competition Authority arrived at our offices in Brussels on June 26 and were joined by Belgian police and the Belgian Competition Authority. The investigators were interested to know whether there was a coordinated effort to restrict supply of immunoglobulin therapies to the Romanian market for the purposes of pressuring the government to exempt these therapies from the “claw back” tax. PPTA cooperated fully with the investigators.
Read More
Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA) +

The pharmaceutical industry represented by AESGP¹, EFPIA², EUCOPE³, EuropaBio⁴, Medicines for Europe and PPTA⁵ – henceforth referred to as ‘the pharmaceutical industry’ – generally welcomes the European Commission (EC)’s Proposal for a Regulation on HTA⁶. We understand the scope of the joint clinical assessments foreseen in the proposal is limited to medicinal products subject to the centralised marketing authorisation, and exempting generic, biosimilar and non-prescription medicines⁷.
Read More

› ‹

Mission Video

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.